Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Sponsor: Novartis Pharmaceuticals
Listed as NCT01223027, this PHASE3 trial focuses on Metastatic Renal Cell Carcinoma and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 7 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Mar 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alcorcón, Spain , Amsterdam, Netherlands , Arezzo, Italy , Aschaffenburg, Germany , Athens, Greece , Athens, United States , Badalona, Spain , Baltimore, United States , Bangkok, Thailand , Barcelona, Spain and 162 more locations